Adropin: The ENHO-Encoded Peptide Regulating Energy Homeostasis, Cardiovascular Function, and Neuroprotection

# Adropin: The ENHO-Encoded Peptide Regulating Energy Homeostasis, Cardiovascular Function, and Neuroprotection

Introduction to Adropin

Adropin is a 76-amino acid secreted peptide hormone encoded by the Energy Homeostasis Associated (ENHO) gene, first characterized by Bharucha Kumar and colleagues in a landmark 2008 publication. The name "adropin" derives from the Latin aduro (to fuel or kindle) and the suffix -in, reflecting its foundational role in energy metabolism. Since its discovery, adropin has emerged as a pleiotropic signaling molecule expressed across multiple organ systems — with particularly high concentrations in the liver and throughout the central nervous system.

Unlike many peptide hormones confined to a single physiological axis, adropin occupies an unusual intersection: it functions as both a hepatokine (liver-derived hormone acting systemically) and a neuropeptide, influencing cardiovascular, metabolic, immune, and neurological pathways simultaneously. This makes it an increasingly valuable subject of preclinical research spanning obesity, type 2 diabetes, cardiovascular disease, stroke, and neurodegenerative conditions.

This article reviews the current body of research on adropin — its biochemistry, mechanisms, and the diverse physiological domains where it appears to exert regulatory activity.

> Research Use Only (RUO) Disclaimer: All information presented here pertains exclusively to laboratory and preclinical research. Adropin is a research chemical; nothing in this article constitutes medical advice, therapeutic recommendations, or guidance for use in humans or animals outside of controlled research settings.

---

Biochemistry and Expression

Gene Structure and Peptide Processing

The human ENHO gene is located on chromosome 9 and encodes a 76-amino acid precursor protein. The secreted bioactive form — adropin-34 — corresponds to the last 34 amino acids (positions 43–76) of the full-length precursor. This processed form is the isoform most studied in extracellular signaling contexts.

ENHO expression is notably diet-responsive. Studies in rodent models demonstrate that high-fat, high-carbohydrate diets suppress ENHO transcription, while caloric restriction and certain macronutrient compositions (particularly lower-fat, lower-carbohydrate intake) upregulate expression. This dietary responsiveness suggests adropin acts as a metabolic sensor, coupling nutritional state to downstream hormonal signaling.

Tissue Distribution

Adropin exhibits broad tissue expression. The primary sites of production include:

• •Liver — the main source of circulating adropin
• •Brain — high expression throughout, especially in cortex, hippocampus, and hypothalamus
• •Heart — both cardiomyocytes and endothelial cells
• •Kidney — moderate expression
• •Small intestine and colon

Circulating plasma adropin levels reflect primarily hepatic secretion, but brain adropin operates in a more autocrine/paracrine capacity as a neurohormone.

---

Metabolic Regulation: Energy Homeostasis and Glucose Metabolism

Foundational Discovery

The 2008 original characterization of adropin by Bharucha Kumar et al. established its role in energy homeostasis. Transgenic mice overexpressing adropin were protected against diet-induced obesity and exhibited improved insulin sensitivity compared to wild-type controls. Conversely, Enho knockout mice developed increased adiposity and greater susceptibility to insulin resistance — a finding replicated in a subsequent 2012 study (PMID 22318315).

These foundational experiments defined adropin as a key regulator of the energy balance equation — influencing both lipid utilization and glucose homeostasis.

Insulin Sensitivity and Hepatic Glucose Production

One of adropin''s most characterized molecular functions is its ability to suppress hepatic glucose output through the PP2A/AMPK signaling axis. Research published in a 2020 study (PMID 32579277) demonstrated that in insulin-resistant hepatocytes, adropin reactivated dampened AMPK signaling by inhibiting protein phosphatase 2A (PP2A), thereby reducing glucose production in the liver.

This mechanism is significant: AMPK is a master cellular energy sensor, and its reactivation by adropin provides a potential bypass of classic insulin receptor dysfunction — a hallmark of type 2 diabetes pathophysiology.

Substrate Utilization and Metabolic Flexibility

A 2015 study published in PNAS (PMID 25830094) examined adropin''s therapeutic effects in diet-induced obese (DIO) mice with established insulin resistance. Adropin administration improved:

• •Glucose tolerance on oral glucose tolerance testing
• •Insulin-stimulated glucose disposal
• •Metabolic flexibility — the ability to shift between lipid and glucose oxidation based on energy demands

Metabolomic analysis revealed reduced incomplete fatty acid oxidation products and an increased CoA/acetyl-CoA ratio, suggesting improved mitochondrial fatty acid utilization. This metabolic flexibility restoration is mechanistically distinct from standard insulin sensitizers, making adropin a unique pharmacological target for preclinical investigation.

Lipid Metabolism and Hepatic Steatosis

Multiple studies have explored adropin''s effects on lipid homeostasis. A 2022 investigation using a type 2 diabetes rodent model (PMID 36077198) found that four weeks of daily adropin treatment:

• •Reduced hepatic lipid content (assessed by histology and biochemical assay)
• •Normalized elevated serum AST and ALT levels (markers of hepatocellular stress)
• •Improved the glucolipid profile including fasting glucose, triglycerides, and HDL cholesterol

In models of non-alcoholic steatohepatitis (NASH), adropin has been shown to activate the Nrf2 antioxidant pathway, reducing reactive oxygen species (ROS) production from liver mitochondria and attenuating lipid peroxidation — implicating it in hepatoprotective signaling beyond simple metabolic regulation.

A 2024 comprehensive review in PMC (PMC11674490) synthesized this evidence, concluding that adropin exerts coordinated regulatory effects across glucose, lipid, and mitochondrial metabolic pathways, with expression levels inversely correlated with metabolic syndrome severity in multiple clinical populations.

---

Cardiovascular Research

Endothelial Function and Vascular Health

Adropin''s cardiovascular effects are mediated substantially through the endothelium. As a hepatokine with direct actions on endothelial cells, adropin promotes nitric oxide (NO) bioavailability by upregulating endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177 — a key activating phosphorylation site.

A 2024 review in PMC (PMC11263719) catalogued adropin''s cardiovascular protective mechanisms:

• •Endothelial barrier preservation — reducing paracellular permeability under oxidative or ischemic stress
• •Anti-atherogenic effects — suppressing foam cell formation and inflammatory cytokine expression in macrophages
• •Vascular smooth muscle modulation — inhibiting osteogenic differentiation of vascular smooth muscle cells via the JAK2/STAT3 pathway, thereby attenuating vascular calcification
• •Blood pressure regulation — linked to reductions in oxidative stress-driven hypertension in preclinical models

Circulating adropin levels in human observational studies have been found to be inversely correlated with markers of endothelial dysfunction, cardiovascular risk scores, and severity of coronary artery disease — positioning adropin as a potential biomarker of vascular health.

Clinical Correlations: Diabetes and Endothelial Dysfunction

A 2025 clinical study (PMID 41125677) examined serum adropin concentrations alongside miR-21 expression as predictors of endothelial dysfunction in patients with type 2 diabetes and established vascular complications. Lower adropin levels were significantly associated with more severe endothelial impairment, supporting its utility as a biomarker — and pointing toward its biological role in preserving vascular integrity under metabolic stress conditions.

Cardiac Fuel Metabolism

Adropin also regulates cardiac substrate preference. A study in PMC (PMC7847067) demonstrated that adropin influences the balance between fatty acid oxidation and glucose utilization in cardiomyocytes. In pathological states where the heart inefficiently oxidizes lipids (as seen in diabetic cardiomyopathy), adropin appears to shift substrate preference toward glucose — a more oxygen-efficient fuel — potentially improving cardiac energetics under stress.

---

Neuroprotection and Central Nervous System Research

Brain Expression and the Neurohormone Concept

A 2025 publication (PMID 40097041) framed adropin as a "cardio-metabolic hormone in the periphery, neurohormone in the brain" — a dual identity that sets it apart from conventional metabolic peptides. Brain adropin is expressed in neurons, astrocytes, and importantly in brain endothelial cells comprising the blood-brain barrier (BBB).

Early research (PMID 27446928) established that adropin in the CNS influences:

• •Hypothalamic energy sensing
• •Glucose uptake in cortical neurons
• •Synaptic plasticity-associated gene expression

Stroke and Blood-Brain Barrier Integrity

The most extensive neuroprotection data concerns ischemic stroke models. Studies using Enho knockout versus adropin-overexpressing mice consistently demonstrate that adropin levels determine stroke severity:

• •Genetic deletion of Enho significantly increased infarct volume and worsened neurological deficits after middle cerebral artery occlusion (MCAO)
• •Overexpression of adropin dramatically reduced stroke volume compared to wild-type controls

The primary mechanism involves eNOS-dependent NO production at the cerebrovascular endothelium. Adropin activates eNOS via Ser1179 phosphorylation, increasing NO bioavailability, reducing neuroinflammation, and preserving BBB tight junction integrity.

A study published in Stroke (PMID 36305313) demonstrated that synthetic adropin administration to aged mice after transient ischemic stroke reduced BBB permeability, brain edema, and infarct size while improving both cognitive and sensorimotor outcomes compared to vehicle-treated controls — with the aged-animal model being particularly notable given that stroke outcomes worsen dramatically with age.

Subarachnoid Hemorrhage

Extending beyond ischemic stroke, a 2024 study in Frontiers in Stroke examined adropin in subarachnoid hemorrhage (SAH). Results showed that SAH significantly decreased adropin expression in cerebrovascular tissue, and that synthetic adropin treatment reversed SAH-associated brain injury and neurobehavioral deficits through sustained eNOS Ser1179 phosphorylation — reaffirming the eNOS axis as a central neuroprotective mechanism.

Broader Neurological Associations

Preclinical and observational research has also linked adropin to:

• •Cognitive function — lower adropin levels associated with greater cognitive impairment in aging cohorts
• •Epilepsy — modified adropin expression observed in animal models of seizure
• •Multiple sclerosis — reduced circulating adropin in MS patients versus controls in observational studies
• •Neurodegenerative disease — exploratory associations with Alzheimer''s and Parkinson''s disease biomarkers in small clinical studies

These associations are correlational and require mechanistic follow-up in controlled research settings, but collectively suggest adropin participates in maintaining CNS homeostasis beyond acute cerebrovascular injury.

---

Immune System Modulation

Immunoregulatory Roles

A 2025 comprehensive review in Frontiers in Immunology (PMC11790448) established adropin as an emerging immunoregulatory peptide. Key findings include:

• •T cell homeostasis — adropin modulates Treg/Th17 balance, with potential anti-inflammatory consequences
• •Macrophage polarization — promotes M2 (anti-inflammatory) macrophage phenotype over M1 (pro-inflammatory)
• •Cytokine regulation — suppresses NF-κB-driven inflammatory cytokine production (TNF-α, IL-6, IL-1β)
• •Mast cell activity — reduces mast cell degranulation in experimental allergy models

Low adropin has been documented in clinical populations with rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease, though directionality of this relationship remains under investigation.

Adipose Tissue Inflammation

In the context of obesity, adipose tissue inflammation drives systemic insulin resistance through continuous pro-inflammatory cytokine secretion. Adropin appears to counteract this by reducing macrophage infiltration into visceral adipose tissue and shifting the inflammatory tone of resident immune cells. This positions adropin at the intersection of metabolic and immune dysfunction — both hallmarks of the metabolic syndrome phenotype.

---

Research Tools and Measurement

Measuring Adropin in Research Models

For researchers working with adropin in laboratory settings, several validated approaches exist:

• •ELISA — commercial ELISA kits for murine and human adropin are widely available and provide quantitative plasma/serum adropin-34 measurements
• •qRT-PCR — for ENHO gene expression quantification in tissue samples
• •Western blot — for protein-level detection in liver and brain tissue homogenates
• •Immunohistochemistry — established protocols for adropin localization in brain and cardiac sections

Synthetic Adropin Peptide

Research groups working on adropin''s causal effects typically use synthetic adropin-34 (the 34 C-terminal amino acids of the full-length precursor). The synthetic peptide is commercially available from multiple peptide synthesis laboratories at >95% HPLC purity for research applications.

Importantly, adropin-34 demonstrates relatively short plasma half-life in rodent pharmacokinetic studies, which has motivated research into PEGylated or acetylated analogs with extended stability for longer-duration studies.

---

Adropin as a Biomarker in Research Cohorts

Clinical Associations

Beyond its role as an active hormone, circulating adropin has attracted considerable interest as a biomarker. Observational research has documented lower serum adropin in:

• •Obese individuals versus lean controls
• •Type 2 diabetes patients versus normoglycemic controls
• •Hypertensive patients with established cardiovascular disease
• •Non-alcoholic fatty liver disease (NAFLD) and NASH
• •Chronic kidney disease patients
• •Major depressive disorder

These cross-sectional associations are hypothesis-generating rather than causal, but they provide a framework for adropin as a readout of metabolic health across multiple organ systems.

Dietary Influences

ENHO expression is strongly diet-responsive. Research in non-human primates (PMID 30988006) demonstrated that animals with low baseline plasma adropin showed greater susceptibility to weight gain and metabolic dysregulation when challenged with a high-sugar diet — suggesting adropin acts as a buffering system against dietary metabolic insult, and that its baseline level may partially predict metabolic resilience.

---

Current Research Landscape and Future Directions

Where Adropin Research Is Heading

The adropin field has matured considerably since 2008. Key research frontiers include:

1. Receptor Identification

Adropin''s receptor has not been definitively identified, which remains a significant gap in mechanistic understanding. GPR19 has been proposed as a candidate receptor based on binding studies, but this requires further validation. Confirming the receptor would enable drug design targeting the adropin signaling axis.

2. Therapeutic Peptide Development

Given adropin''s broad protective effects across metabolic, cardiovascular, and neurological systems, there is significant interest in developing stable adropin analogs with improved pharmacokinetic profiles for preclinical studies. Current limitations include rapid plasma clearance and susceptibility to proteolytic degradation.

3. Adropin-Gut Microbiome Axis

Emerging research suggests that gut microbiota composition influences hepatic ENHO expression, potentially linking microbiome dysbiosis to reduced adropin production in metabolic syndrome. This is an area of early but growing investigation.

4. Sex Differences

Preliminary data suggests sex-specific differences in adropin expression and responsiveness, particularly in cardiovascular and metabolic contexts. Whether these reflect hormonal regulation of ENHO (e.g., by estrogen) is under investigation.

5. Nonhuman Primate and Human Interventional Studies

Whereas most mechanistic data derives from rodent models, there is a recognized need for nonhuman primate studies to bridge the gap toward potential human research applications.

---

Summary

Adropin (encoded by ENHO) is a pleiotropic secreted peptide with documented regulatory roles in energy homeostasis, insulin sensitivity, lipid metabolism, cardiovascular function, neuroprotection, and immune modulation. Key research highlights include:

• •Metabolic axis: Adropin activates hepatic AMPK via PP2A inhibition, reducing glucose output and improving insulin sensitivity; it also restores metabolic flexibility toward glucose utilization in obese/diabetic models
• •Cardiovascular axis: Adropin preserves endothelial function via eNOS activation, reduces vascular calcification, and has anti-atherogenic properties; circulating levels inversely correlate with cardiovascular risk markers
• •Neurological axis: Adropin protects the blood-brain barrier, reduces ischemic infarct volume through eNOS-dependent NO production, and is neuroprotective in multiple stroke models
• •Immune axis: Adropin promotes anti-inflammatory polarization of macrophages, modulates T-cell balance, and suppresses NF-κB-driven cytokine production

As research tools and synthetic adropin peptides become more accessible, adropin represents a compelling target for basic research into the integrated biology of metabolic-vascular-neurological health axes.

---

References

2. Butler AA et al. (2012). Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity. PubMed

3. Gao S et al. (2015). Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Molecular Metabolism. PMC

4. Gao S et al. (2020). Adropin regulates hepatic glucose production via PP2A/AMPK pathway in insulin-resistant hepatocytes. Biochemical and Biophysical Research Communications. PubMed

5. Rao S et al. (2021). Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism. American Journal of Physiology. PMC

6. Lian W et al. (2021). Neurovascular protection by adropin in experimental ischemic stroke through an eNOS-dependent mechanism. Journal of Cerebral Blood Flow & Metabolism. PMC

7. Thapa K et al. (2022). Therapeutic Benefits of Adropin in Aged Mice After Transient Ischemic Stroke via Reduction of Blood-Brain Barrier Damage. Stroke. PubMed

8. Xin J et al. (2022). Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile and Liver Markers. Nutrients. PubMed

9. Butler AA et al. (2019). Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in nonhuman primates. Cell Reports Medicine. PubMed

10. Zhang C et al. (2024). Adropin: A crucial regulator of cardiovascular health and metabolic balance. PMC. PMC

11. Meng Q et al. (2024). Role of the Unique Secreted Peptide Adropin in Various Physiological and Disease States. Biomolecules. PMC

12. Chen X et al. (2025). Adropin: a key player in immune cell homeostasis and regulation of inflammation. Frontiers in Immunology. PMC

13. Viswambharan H et al. (2025). Adropin: A cardio-metabolic hormone in the periphery, a neurohormone in the brain? American Journal of Physiology. PubMed

14. Khalaf M et al. (2025). Serum adropin and miR-21 as predictors of endothelial dysfunction in type 2 diabetes. PubMed

---

Further Reading:

• •Ghrelin: The Acylated Gastric Peptide Driving Growth Hormone, Energy Homeostasis, and Neuroprotection Research
• •Peptide vs Protein: Understanding Size, Structure, and Functional Differences in Research
• •Peptide Degradation and Storage: Temperature, Light, and Reconstitution Science
• •Understanding Peptide Purity: What HPLC Percentages Actually Mean for Research
• •Peptide Stack Builder
• •Dosage Chart